

TORRENT PHARMACEUTICALS LIMITED

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2008

[Rs. in Lacs except per share data]

PARTICULARS	QUARTER ENDED		YEAR ENDED
	30-Jun-08	30-Jun-07	31-Mar-08
Sales (see note 2)	28323	24478	97549
Less: Excise Duty collected	101	171	599
Net Sales	28222	24307	96950
Other Operating Income	518	326	2640
Other Income	91	25	465
Total Income	28831	24658	100055
Expenditure			
(Increase) / Decrease in Stock in Trade	742	(548)	2045
Consumption of Raw / Packing Materials	9065	6975	28487
Purchase of Traded Goods	1215	2013	5084
Employees Cost	3450	3075	11482
Research and Development Expenses	2488	2032	9141
Depreciation and Amortisation	790	812	3274
Other Expenditure	5209	6086	22118
Total Expenditure	22959	20445	81631
Net Borrowing Costs	557	391	1840
Profit from Ordinary Activities before tax	5315	3822	16584
Tax Expense	164	498	1032
Net Profit from Ordinary Activities after tax	5151	3324	15552
Paid-up Equity Share Capital [Face Value Rs.5]	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	54294
Basic and Diluted EPS for the period	6.09	3.93	18.38
Public shareholding			
Number of shares	21922832	21919832	21922832
Percentage of shareholding	25.91%	25.91%	25.91%

Notes :

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 29-Jul-08. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter Ended			Rs. in Lacs
	30-Jun-08	30-Jun-07	Growth %	Year Ended 31-Mar-08
Domestic Formulations	17217	17175	-	58732
Exports	7337	4249	73%	23591
Contract Manufacture	3729	3001	24%	14902
Others	40	53	-	324
Gross Sales	28323	24478	16%	97549
Less : Excise duty	101	171	-	599
Net Sales	28222	24307	16%	96950

- 3 During the quarter, the Company borrowed unsecured long term loan of Rs. 7998 Lacs.
- 4 During the quarter, no investor complaints were received. No complaints were pending at the beginning of the quarter.
- 5 The Company has also prepared and published unaudited consolidated financial results for the quarter ended, which were subjected to limited review by the statutory auditors of the Company.

For TORRENT PHARMACEUTICALS LIMITED

Place : Ahmedabad
Date : 29-Jul-08

sd/-
SUDHIR MEHTA
Chairman

... Visit us at www.torrentpharma.com....